Boehringer Ingelheim o phatlalalitse kajeno hore US Food and Drug Administration (FDA) e file Breakthrough Therapy Designation ho mofuta oa eona oa kalafo oa lipatlisiso, BI 1015550, bakeng sa kalafo ea idiopathic pulmonary fibrosis (IPF). BI 1015550 ke inhibitor ea molomo, phosphodiesterase 4B (PDE4B) e nang le monyetla oa ho sebetsana le pulmonary fibrosis - leqeba le ke keng la thijoa la lisele tsa matšoafo le amang ts'ebetso ea matšoafo hampe - le ho ruruha ho amanang le mafu a tsoelang pele a mats'oafo a "fibrosing interstitial" (ILDs).
"Ntšetso-pele e potlakileng ea BI 1015550 ke karolo ea leqhubu le latelang la Boehringer Ingelheim la mekhoa e mecha ea phekolo bakeng sa mafu a matšoafo a matšoafo a reretsoeng ho boloka ts'ebetso ea matšoafo le ho ntlafatsa bophelo ba bakuli," ho boletse Thomas Seck, MD, motlatsi oa motlatsi oa mopresidente, Meriana le Litaba tsa Taolo. Boehringer Ingelheim Pharmaceuticals, Inc. “BI 1015550 e emetse molek'hule oa pele sehlopheng sa PDE4B inhibitors e ntseng e ithutoa bakeng sa IPF le li-ILD tse ling tse tsoelang pele tsa fibrosing. Re thehile holim'a lefa la rona ho pulmonary fibrosis mme re ntse re sebetsa ho latela sephetho le tlhaiso-leseling ea bongaka ka sepheo sa hore moriana ona o mocha o ka fihlela bakuli kapele kamoo ho ka khonehang. ”
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs).
- We have built on our heritage in pulmonary fibrosis and are acting on the breakthrough designation and clinical data with the goal that this potential novel medicine can reach patients as soon as possible.
- “The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients,”.